Insider buying last 90 days
No open-market insider purchases were filed for RVTY in the last 90 days.
From Form 4 filings, dated to when each was filed.
Nov 13 close
Revvity's shares advanced this week on strong third quarter results, with pro forma revenue rising 7% year-over-year to $710 million and statutory earnings per share beating forecasts by 13%, driven by the Life Sciences and Diagnostics segments. The results prompted a wave of analyst price target increases, including Barclays lifting its target to $175 from $160 while maintaining an Equal-Weight rating, and TD Cowen raising its target to $185 from $175 while reiterating a Buy rating. A separate rating upgrade to Buy was also noted, alongside commentary suggesting that while organic revenue and AI-driven demand remain strong, current valuations may already reflect expected improvement.
Revvity closed at $160.72, up 3.6%, sitting above both its 50-day average of $148.16 and its 200-day average of $113.14, with the 50-day above the 200-day. The GekkoIndex reads 55, placing the stock in the Neutral zone. Price stands 17.9% above Gekko Fair Value of $136.36, a gap that contrasts with the consensus target of $149.87 from 14 firms, six rating it Buy and eight Hold.
The next earnings report is scheduled for 1 February 2027, 78 days away, placing it outside a typical 20-trading-day holding window. No insider, Congress, or unusual options activity appears in the respective 90-day and 30-day windows. Seasonality data shows the next 20 trading days have averaged a 4.3% gain over 5 years, rising in 4 of them, a pattern worth noting alongside the current gap to Gekko Fair Value.
Written by AI from the Nov 9, 2026 close and checked automatically against the figures on this page.
Revvity scores 4 supportive, 1 mixed and 1 headwind across the 6 checklist items with data.
Six things swing traders check before a 20-day hold, read from the latest data.
4 supportive1 mixed1 headwind
Above 50 and 200-day
Close $154.39 is above the 50-day ($150.40) and 200-day ($114.03) averages, and the 50-day is above the 200-day.
See the chart59.7, Neutral
Reading 59.7 is in the Neutral zone.
See the GekkoIndex8.9% above
Price is 8.9% above Gekko Fair Value (more than 5% above).
See fair valueLeans bullish
Last 30 days: 1 unusual options signal.
See smart moneyReports in 78 days
Next report Feb 1, 2027, 78 days away — outside a typical 20-trading-day hold.
See earnings+3.8% on average
From this point in the calendar, the next 20 trading days averaged +3.8% over 5 years, rising in 3 of them.
See seasonalityA description of current data, not a recommendation. How this page works
Revvity closed at $154.39 on Nov 13, 2026, +64.0% over the past year, inside a 52-week range of $81.22 to $171.74.
Use the left and right arrow keys to read daily values.
Put RVTY on a Gekko watchlist and see its GekkoIndex, Gekko Fair Value and smart money signals update on the chart as they change.
Revvity supplies instruments, reagents, software and related services used in scientific research and health screening. The company works across life sciences and diagnostics, offering tools such as detection and imaging technology, laboratory instrumentation, and testing platforms used to identify genetic and infectious conditions. It is recognized for products that support screening for disorders such as Down syndrome and metabolic conditions, as well as tools used in genomic research.
The company operates through two main areas. One focuses on instruments, reagents, informatics and contract laboratory work for life sciences research, environmental testing, agriculture and food analysis, and industrial applications like chemicals, semiconductors and energy. The other centers on diagnostics, providing assay systems and sequencing-based tools used in prenatal and childhood screening, infectious disease testing, oncology and drug discovery. Its customers include pharmaceutical and biotechnology firms, laboratories, academic institutions, healthcare providers, public health agencies and government organizations.
Revvity's shares are listed on the NYSE under the ticker RVTY.
Revvity’s GekkoIndex — Gekko’s 0 to 100 smart money score — reads 59.7, in the Neutral zone, up 2.8 points over five sessions.
Up 2.8 points over five sessions.
Reading for Nov 13, 2026
| Zone | Readings | 5 days | 20 days | ||
|---|---|---|---|---|---|
| Buying | 19 | +1.8% | +2.8% | ||
| Accumulation | 251 | +0.5% | +1.2% | ||
| Neutral (current zone) | 388 | +0.4% | +2.0% | ||
| Distribution | 43 | −1.2% | −2.1% | ||
| Selling | 1 | Too few readings yet | |||
Average RVTY share-price change over the trading days after each daily reading in its GekkoIndex history. Across every stock Gekko tracks, Neutral readings averaged +0.9% over 20 days. Past behaviour doesn’t guarantee future results.
Neutral zone: No clear directional signal. About the five zones →
Revvity trades 8.9% above Gekko Fair Value of $141.76, so the shares are overvalued on Gekko’s estimate.
Gekko’s own estimate of what Revvity shares are worth, recalculated every trading day.
$141.76
Gekko Fair Value, Nov 14, 2026
8.9% Overvalued
At the end of Aug 2026 the price was 18.1% above the estimate.
No open-market insider purchases were filed for Revvity, and no Congress trades were disclosed, in the last 90 days.
Plus buybacks, unusual options and fund positions, each dated to when it became public.
No open-market insider purchases were filed for RVTY in the last 90 days.
From Form 4 filings, dated to when each was filed.
No trades in RVTY were disclosed by members of Congress in the last 90 days.
From congressional disclosures, which report amounts as ranges.
Revvity has been buying back its own shares.
From company filings.
1signal, 74% of the flagged premium in calls.
Latest: Bullish flow on Nov 11, $366K in unusual premium.
Revvity reports on Feb 1, 2027, before the open (78 days away), and beat the EPS estimate in 8 of its last 8 reports.
Feb 1, 2027
Expected before the open, 78 days away
| Reported | EPS | Revenue | Move |
|---|---|---|---|
| Aug 4, 2026 | $1.41 est $1.21 | $711.0M est $703.0M | −0.2% |
| May 5, 2026 | $1.06 est $1.02 | $711.1M est $704.1M | +14.5% |
| Feb 2, 2026 | $1.70 est $1.57 | $772.1M est $764.9M | −7.0% |
| Oct 27, 2025 | $1.18 est $1.14 | $698.9M est $699.4M | −2.5% |
| Jul 28, 2025 | $1.18 est $1.14 | $720.3M est $699.9M | −8.9% |
| Apr 28, 2025 | $1.01 est $0.96 | $664.8M est $710.8M | +0.4% |
| Jan 31, 2025 | $1.42 est $1.38 | $729.4M est $665.3M | −2.5% |
| Nov 4, 2024 | $1.28 est $1.13 | $684.0M est $679.7M | +4.1% |
“Move” is the close of the first session after the report compared with the close of the last session before it, so it reads the same whether the company reported before the open or after the close.
Analysts’ average 12-month price target for Revvity is $171.07, +10.8% from the last close, from 14 firms rating the stock in the last 90 days.
Each firm’s latest rating in the last 90 days: 14 firms.
| Date | Firm | Target | vs price |
|---|---|---|---|
| Nov 12 | Bernstein | $160 | +3.6% |
| Nov 5 | Leerink Partners | $180 | +16.6% |
| Nov 4 | Stifel Nicolaus | $177 | +14.6% |
| Nov 4 | J.P. Morgan | $160 | +3.6% |
| Nov 4 | Robert W. Baird | $190 | +23.1% |
Gekko doesn’t publish price predictions. These are analyst targets and historical base rates, which don’t guarantee future results.
Over the next 20 trading days from Nov 14, Revvity averaged +3.8% across the last 5 years, rising in 3 of them.
| Window | Average | Years higher |
|---|---|---|
| Next 5 trading days | −1.1% | 2 of 5 |
| Next 10 trading days | +0.4% | 2 of 5 |
| Next 15 trading days | +0.8% | 3 of 5 |
| Next 20 trading days | +3.8% | 3 of 5 |
| Next 30 trading days | +5.8% | 3 of 5 |
For scale, RVTY’s typical 20-trading-day move in either direction is about 5.8%.
Revvity’s market cap is $17.24B, with a P/E ratio of 70.4 and revenue of $2.94B over the last twelve months.
Coverage of Revvity this week reads positive: 5 positive, 2 neutral and 2 negative headlines.
Revvity’s 6 largest industry peers by market value, with today’s move, GekkoIndex zone and gap to Gekko Fair Value.
| Stock | GekkoIndex zone | vs Fair Value |
|---|---|---|
| TMOThermo Fisher Scientific | Neutral | 15.0% above |
| ABTAbbott Laboratories | Neutral | 10.5% below |
| DHRDanaher | Neutral | 4.7% above |
| ISRGIntuitive Surgical | Neutral | 17.5% above |
| MDTMedtronic | Neutral | 14.2% below |
| SYKStryker | Neutral | 0.1% below |
A peer links to its own page where one exists.
Revvity’s market cap is $17.24B at the Nov 13, 2026 close of $154.39, with 111.6M shares outstanding. The shares trade on a P/E ratio of 70.4.
The consensus analyst 12-month price target for Revvity is $171.07, +10.8% from the last close. Of the 14 firms that rated the stock in the last 90 days, 6 rate it a buy, 8 a hold and 0 a sell. Gekko doesn’t publish price predictions of its own.
On Gekko’s estimate Revvity is overvalued: the Nov 13, 2026 close of $154.39 is 8.9% above Gekko Fair Value of $141.76. Gekko Fair Value is recalculated every trading day, and a gap inside 5% either way counts as about fair value.
Revvity is expected to report on Feb 1, 2027, before the market opens (78 days away). Analysts expect earnings of $1.61 per share on revenue of $759.1M. Revvity beat the earnings estimate in 8 of its last 8 reports, moving 5% on average across the report.
Revvity’s 52-week high is $171.74 and its 52-week low is $81.22; it closed at $154.39 on Nov 13, 2026, +64.0% over the past year. Over the last five years the shares peaked at $203.16 on Dec 31, 2021.
Gekko describes the data; it does not make buy or sell recommendations. On the swing-trade checklist, 4 of the 6 items with data read as supportive (trend, smart money, earnings risk and seasonality), 1 as mixed (gekkoindex) and 1 as a headwind (fair value). The checklist is a description of current data, not a recommendation.
Gekko flagged 1 unusual options signal in Revvity over the last 30 days, with $271K of flagged premium in calls and $95K in puts. The latest, bullish flow, was on Nov 11, 2026 with $366K in unusual premium. The signal-by-signal table is in Gekko.
During US trading hours the price at the top of the page is a delayed quote, refreshed every 15 minutes; everything else is rebuilt after each US market close. The GekkoIndex, Gekko Fair Value and the checklist are Gekko’s own, and the Gekko Brief is written by AI from this page’s data and checked against it before it is published. How Gekko’s data works →
Every GekkoIndex reading, insider trade, options bet and Congress disclosure plotted on the chart, plus the 5,800-name screener and trade planning tools.
Join 1,475 other traders using Gekko
Start Your FREE 7 Day Trial → Every feature unlocked. No credit card required.Type a ticker or company name. Press Esc to close.